New Acquisitions Joins 20th Anniversary PanCAN PurpleStride to Honor Survivors & Support Fight Against Pancreatic Cancer

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call - Nanobiotix (NASDAQ:NBTX)

Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by Principal Investigator Eugene Koay, MD, at ESTRO 2025 on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CEST Nanobiotix will host an event on Monday, May 5th at 8:00 AM EDT / 2:00 PM CEST to review the …

New Acquisitions Joins 20th Anniversary PanCAN PurpleStride to Honor Survivors & Support Fight Against Pancreatic Cancer

New Acquisitions joined PanCAN’s 20th PurpleStride 5K in Atlanta, walking for awareness and in support of our HR Manager’s mom, a proud cancer survivor. ATLANTA, GA, UNITED STATES, April 30, 2025 /EINPresswire.com/ -- New Acquisitions was proud to participate in the 20th anniversary of the PanCAN PurpleStride 5K, standing alongside thousands nationwide to raise awareness and support for pancreatic cancer research. This marks our second year join…

Pancreatic cancer in the spotlight

Read our TCS London Marathon highlights as we celebrate being Charity of the Year, and how we are one step closer to funding the ultimate test.